Metivia-Anne Whitmore, DO
Family Medicine · Jamestown, NYNPI 1982695839
Payments from drug & device makers
Across 270 payments — averaging $18.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$920
- Pfizer$582
- Novo Nordisk$527
- Astellas Pharma US Inc$351
- AstraZeneca$282
- AbbVie$266
- plus $2K from 31 others
Across 2 payments — averaging $236.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dexcom, Inc.$472
What the payments were for
- Food & beverage$4,85698%
- Education$852%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 61 | $920 |
| Pfizer | 32 | $582 |
| Novo Nordisk | 29 | $527 |
| Astellas Pharma US Inc | 14 | $351 |
| AstraZeneca | 17 | $282 |
| AbbVie | 12 | $266 |
| Bayer | 12 | $253 |
| Dexcom, Inc. | 12 | $217 |
| Lilly USA, LLC | 12 | $192 |
| Merck | 9 | $157 |
| Sumitomo Pharma America, Inc. | 4 | $93 |
| Sanofi-aventis U.S. LLC | 5 | $90 |
| Baxter Healthcare | 2 | $87 |
| Johnson & Johnson | 3 | $79 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $79 |
| Amgen | 5 | $76 |
| Phathom Pharmaceuticals, Inc. | 3 | $75 |
| Boehringer Ingelheim | 5 | $72 |
| Boston Scientific | 4 | $70 |
| Exact Sciences | 3 | $69 |
| Mylan Specialty L.p. | 4 | $69 |
| Otsuka America Pharmaceutical, Inc. | 3 | $59 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $24 |
| Lundbeck LLC | 1 | $23 |
| Exeltis, USA Inc. | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $21 |
| Medtronic | 1 | $19 |
| Cumberland Pharmaceuticals, Inc. | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Metacel Pharmaceuticals LLC | 1 | $17 |
| Gilead | 1 | $16 |
| Shield Therapeutics Inc | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Vertex | 1 | $15 |
| Galderma Laboratories, L.p. | 1 | $14 |
How this compares
$4,941 in reported general payments places this provider in the 85th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 75 | $106,196 |
| EliquisApixaban | 104 | $103,739 |
| JardianceEmpagliflozin | 78 | $99,878 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 67 | $70,316 |
| TrulicityDulaglutide | 37 | $60,781 |
| FarxigaDapagliflozin Propanediol | 34 | $44,805 |
| KerendiaFinerenone | 38 | $44,179 |
| ProliaDenosumab | 11 | $18,666 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $15,025 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 16 | $12,350 |
| Xtampza ErOxycodone Myristate | 13 | $9,854 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 22 | $7,078 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 26 | $5,887 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 17 | $5,514 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $4,816 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $582 | $109,253121 claims |
| Novo NordiskOzempic | $527 | $106,19675 claims |
| Boehringer IngelheimJardiance | $72 | $99,87878 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Shingrix | $920 | $98,307143 claims |
| Lilly USA, LLCTrulicity | $192 | $60,78137 claims |
| AstraZenecaFarxiga | $282 | $44,80534 claims |
| BayerKerendia | $253 | $44,17938 claims |
| AmgenProlia | $76 | $18,66611 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $18 | $2,786220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,321 family medicine providers in New York.
Other family medicine in Jamestown
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.